Cover Image
Market Research Report
Product code 
1069319

Human Genetics Market-Forecast till 2027

Published: | Market Research Future | 169 Pages | Delivery time: 1-2 business days

Price

Back to Top
Human Genetics Market-Forecast till 2027
Published: March 28, 2022
Market Research Future
Content info: 169 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Market Snapshot

The global human genetics market is anticipated to register a substantial market expansion at a notable CAGR of 17.76% during the review period to surpass USD 1,12,536.54 million by 2027.

Human genetics is the investigation of the conveyance of qualities through ages. Adjustment in the genome might bring about change, a little piece of which might prompt the infection aggregate. Hereditary sicknesses can be monogenic, multifactorial, and chromosomal are passed down from the guardians to the descendants by various legacy designs, for example, X-connected latent, autosomal passive, and autosomal prevailing. Developing predominance of epilepsy among the geriatric populace go about as significant driver in the worldwide human genetics market during 2021-2027. Nonetheless, significant expense of hereditary testing impedes the development of the worldwide human genetics market during the conjecture time frame. The developing utilization of hereditary information across medical services and innovative progression in hereditary testing is relied upon to set out a freedom in the worldwide human genetics market.

Market Segmentation

Global Human Genetics Market has been segregated based on Application, and test.

Based on application the global market has been classified into Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment, Oncology, Cardiology, Assisted Reproduction, Neurology, Gynaecology, and others.

The neurology segment is further sub-divided into Neuropediatric and Others. Based on the Test segment, the Global Human Genetics Market has been categorized into NIPT, Carrier Testing, Pharmacogenomic Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, and others.

Regional Analysis

Geographically, the global human genetics market, has been studied across the US, Canada, UK, Germany, Spain, Japan, Others.

The human genetics market in the US benefits from a high medical care use, expanding interest for hereditary testing by the populace, and high open mindfulness with respect to early discovery of infections and preventive consideration. Also, the accessibility of repayments in the US for hereditary tests further develops market development in the country.

Genomic wellbeing information in the UK is created in three significant regions, including enormous scope research programs, the medical services framework, and buying of direct-to-purchaser hereditary testing. Additionally, the ascent in the number of drives embraced by people in general as well as private associations is further supporting the market development.

In Germany, the rising commonness of hereditary issues, disease, expanding mindfulness and acknowledgment regarding customized meds, and developing spotlight on R&D exercises add to the nation's development. Also, the public authority is executing various good and cooperative approaches to consolidate hereditary testing into the medical care framework and give protection repayments to residents, which, thusly, is driving the market development.

DNA testing at home in Japan is acquiring a foothold among the older populace looking for answers in regard to their wellbeing and illness chances.

Major Players

The Key Companies operating in the global human genetics market includes GENinCode (UK), Atrys Health (Spain), Genyca (Spain), Igenomix (India), Genologica (Spain), Myriad Genetics (US), NIMGenetics (Spain), Sistemas Genomicos (Spain), FullGenomics (Spain), Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), and Bode Technology Group Inc (US).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/0243-CR

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

  • 2.1 DEFINITION 15
  • 2.2 SCOPE OF THE STUDY 15
  • 2.3 RESEARCH OBJECTIVE 15
  • 2.4 MARKET STRUCTURE 15
  • 2.5 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

  • 3.1 DATA MINING 17
  • 3.2 SECONDARY RESEARCH 18
  • 3.3 PRIMARY RESEARCH 19
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
  • 3.5 FORECASTING TECHNIQUES 21
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
    • 3.6.1 BOTTOM-UP APPROACH 23
    • 3.6.2 TOP-DOWN APPROACH 23
  • 3.7 DATA TRIANGULATION 24
  • 3.8 VALIDATION 24

4 MARKET DYNAMICS 25

  • 4.1 OVERVIEW 25
  • 4.2 DRIVERS 26
    • 4.2.1 GROWING ADOPTION OF GENETIC TESTING 26
    • 4.2.2 INCREASING INCIDENCES OF GENETIC DISEASES AND CANCER 26
  • 4.3 RESTRAINTS 27
    • 4.3.1 HIGH COST OF GENETIC TESTING 27
    • 4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED GENETIC COUNSELORS 27
  • 4.4 OPPORTUNITY 28
    • 4.4.1 GROWING USE OF GENETIC DATA ACROSS HEALTHCARE AND TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING 28

5 MARKET FACTOR ANALYSIS 29

  • 5.1 VALUE CHAIN ANALYSIS 29
    • 5.1.1 R&D 30
    • 5.1.2 MANUFACTURING 30
    • 5.1.3 DISTRIBUTION & SALES 30
    • 5.1.4 POST-SALES MONITORING 30
  • 5.2 PORTER'S FIVE FORCES MODEL 31
    • 5.2.1 THREAT OF NEW ENTRANTS 31
    • 5.2.2 BARGAINING POWER OF SUPPLIERS 32
    • 5.2.3 THREAT OF SUBSTITUTES 32
    • 5.2.4 BARGAINING POWER OF BUYERS 32
    • 5.2.5 INTENSITY OF RIVALRY 32
  • 5.3 IMPACT OF COVID-19 ON THE GLOBAL HUMAN GENETICS MARKET 32
    • 5.3.1 IMPACT ON SUPPLY CHAIN 32
    • 5.3.2 IMPACT ON PATIENTS SUFFERING FROM GENETIC DISEASES 33
    • 5.3.3 IMPACT ON KEY PLAYERS 33

6 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION 34

  • 6.1 OVERVIEW 34
  • 6.2 WELLNESS & E-COMMERCE 35
  • 6.3 PREVENTIVE MEDICINE 35
  • 6.4 DIAGNOSTIC & TREATMENT 36

7 GLOBAL HUMAN GENETICS MARKET, BY TEST 42

  • 7.1 OVERVIEW 42
  • 7.2 NIPT 43
  • 7.3 CARRIER TESTING 44
  • 7.4 PHARMACOGENOMIC TESTING 45
  • 7.5 KARYOTYPE TESTING 46
  • 7.6 THROMBOPHILIA TESTING 47
  • 7.7 SEPTIN 9 BIOMARKER TESTING 48
  • 7.8 NGS 49
  • 7.9 OTHERS 51

8 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY 52

  • 8.1 OVERVIEW 52
    • 8.1.1 US 53
    • 8.1.2 CANADA 55
    • 8.1.3 UK 57
    • 8.1.4 GERMANY 59
    • 8.1.5 SPAIN 61
    • 8.1.6 JAPAN 63
    • 8.1.7 OTHERS 65

9 COMPETITIVE LANDSCAPE 67

  • 9.1 OVERVIEW 67
  • 9.2 COMPETITIVE BENCHMARKING 68
  • 9.3 MAJOR GROWTH STRATEGY IN THE HUMAN GENETICS MARKET 69
  • 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE HUMAN GENETICS MARKET 70
  • 9.5 KEY DEVELOPMENT ANALYSIS 71
  • 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 71
    • 9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 71
    • 9.6.2 MERGER &ACQUISITION 71
    • 9.6.3 EXPANSION 72
  • 9.7 FINANCIAL MATRIX 72
    • 9.7.1 SALES (USD MILLION), 2020 72

10 COMPANY PROFILES 73

  • 10.1 MYRIAD GENETICS, INC. 73
    • 10.1.1 COMPANY OVERVIEW 73
    • 10.1.2 FINANCIAL OVERVIEW 74
    • 10.1.3 PRODUCT/SERVICE OFFERED 75
    • 10.1.4 KEY DEVELOPMENTS 75
    • 10.1.5 SWOT ANALYSIS 76
    • 10.1.6 KEY STRATEGIES 76
  • 10.2 SYNLAB GROUP 77
    • 10.2.1 COMPANY OVERVIEW 77
    • 10.2.2 FINANCIAL OVERVIEW 77
    • 10.2.3 PRODUCT/SERVICE OFFERED 78
    • 10.2.4 KEY DEVELOPMENTS 78
    • 10.2.5 SWOT ANALYSIS 79
    • 10.2.6 KEY STRATEGIES 79
  • 10.3 EUROFINS MEGALAB S.A. 80
    • 10.3.1 COMPANY OVERVIEWS 80
    • 10.3.2 FINANCIAL OVERVIEW 80
    • 10.3.3 PRODUCT/SERVICE OFFERED 81
    • 10.3.4 KEY DEVELOPMENTS 81
    • 10.3.5 SWOT ANALYSIS 81
    • 10.3.6 KEY STRATEGIES 82
  • 10.4 BIOMARKER TECHNOLOGIES. 83
    • 10.4.1 COMPANY OVERVIEW 83
    • 10.4.2 FINANCIAL OVERVIEW 83
    • 10.4.3 PRODUCT/SERVICE OFFERED 83
    • 10.4.4 KEY DEVELOPMENTS 83
    • 10.4.5 SWOT ANALYSIS 84
    • 10.4.6 KEY STRATEGIES 84
  • 10.5 ECHEVARNE LABORATORY 85
    • 10.5.1 COMPANY OVERVIEW 85
    • 10.5.2 FINANCIAL OVERVIEW 85
    • 10.5.3 PRODUCT/SERVICE OFFERED 85
    • 10.5.4 KEY DEVELOPMENTS 85
    • 10.5.5 SWOT ANALYSIS 86
    • 10.5.6 KEY STRATEGIES 86
  • 10.6 ELABSCIENCE BIOTECHNOLOGY INC. 87
    • 10.6.1 COMPANY OVERVIEW 87
    • 10.6.2 FINANCIAL OVERVIEW 87
    • 10.6.3 PRODUCT/SERVICE OFFERED 87
    • 10.6.4 KEY DEVELOPMENTS 87
    • 10.6.5 SWOT ANALYSIS 88
    • 10.6.6 KEY STRATEGIES 88
  • 10.7 NIMGENETICS 89
    • 10.7.1 COMPANY OVERVIEW 89
    • 10.7.2 FINANCIAL OVERVIEW 89
    • 10.7.3 PRODUCT/SERVICE OFFERED 89
    • 10.7.4 KEY DEVELOPMENTS 90
    • 10.7.5 SWOT ANALYSIS 90
    • 10.7.6 KEY STRATEGIES 90
  • 10.8 SISTEMAS GENOMICOS 91
    • 10.8.1 COMPANY OVERVIEW 91
    • 10.8.2 FINANCIAL OVERVIEW 91
    • 10.8.3 PRODUCTS/SERVICES OFFERED 91
    • 10.8.4 KEY DEVELOPMENTS 91
    • 10.8.5 SWOT ANALYSIS 92
    • 10.8.6 KEY STRATEGIES 92
  • 10.9 FULLGENOMICS 93
    • 10.9.1 COMPANY OVERVIEW 93
    • 10.9.2 FINANCIAL OVERVIEW 93
    • 10.9.3 PRODUCTS/SERVICES OFFERED 93
    • 10.9.4 KEY DEVELOPMENTS 93
    • 10.9.5 SWOT ANALYSIS 94
    • 10.9.6 KEY STRATEGIES 94
  • 10.10 GENINCODE 95
    • 10.10.1 COMPANY OVERVIEW 95
    • 10.10.2 FINANCIAL OVERVIEW 95
    • 10.10.3 PRODUCTS/SERVICES OFFERED 95
    • 10.10.4 KEY DEVELOPMENTS 95
    • 10.10.5 SWOT ANALYSIS 96
    • 10.10.6 KEY STRATEGIES 96
  • 10.11 ATRYS HEALTH 97
    • 10.11.1 COMPANY OVERVIEW 97
    • 10.11.2 FINANCIAL OVERVIEW 97
    • 10.11.3 PRODUCTS/SERVICES OFFERED 97
    • 10.11.4 KEY DEVELOPMENTS 97
    • 10.11.5 SWOT ANALYSIS 98
    • 10.11.6 KEY STRATEGIES 98
  • 10.12 GENYCA 99
    • 10.12.1 COMPANY OVERVIEW 99
    • 10.12.2 FINANCIAL OVERVIEW 99
    • 10.12.3 PRODUCTS/SERVICES OFFERED 99
    • 10.12.4 KEY DEVELOPMENTS 99
    • 10.12.5 SWOT ANALYSIS 100
    • 10.12.6 KEY STRATEGIES 100
  • 10.13 IGENOMIX 101
    • 10.13.1 COMPANY OVERVIEW 101
    • 10.13.2 FINANCIAL OVERVIEW 101
    • 10.13.3 PRODUCTS/SERVICES OFFERED 101
    • 10.13.4 KEY DEVELOPMENTS 101
    • 10.13.5 SWOT ANALYSIS 102
    • 10.13.6 KEY STRATEGIES 102
  • 10.14 GENOLOGICA 103
    • 10.14.1 COMPANY OVERVIEW 103
    • 10.14.2 FINANCIAL OVERVIEW 103
    • 10.14.3 PRODUCTS/SERVICES OFFERED 103
    • 10.14.4 KEY DEVELOPMENTS 103
    • 10.14.5 SWOT ANALYSIS 104
    • 10.14.6 KEY STRATEGIES 104
  • 10.15 BODE CELLMARK FORENSICS, INC. 105
    • 10.15.1 COMPANY OVERVIEW 105
    • 10.15.2 FINANCIAL OVERVIEW 105
    • 10.15.3 PRODUCTS/SERVICES OFFERED 105
    • 10.15.4 KEY DEVELOPMENTS 105
    • 10.15.5 SWOT ANALYSIS 106
    • 10.15.6 KEY STRATEGIES 106

11 APPENDIX 107

  • 11.1 REFERENCES 107
  • 11.2 RELATED REPORTS 107

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
  • TABLE 3 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 34
  • TABLE 4 GLOBAL HUMAN GENETICS MARKET FOR WELLNESS & E-COMMERCE, BY COUNTRY, 2018-2027 (USD MILLION) 35
  • TABLE 5 GLOBAL HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY COUNTRY, 2018-2027 (USD MILLION) 36
  • TABLE 6 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY COUNTRY, 2018-2027 (USD MILLION) 37
  • TABLE 7 GLOBAL HUMAN GENETICS MARKET FOR APPLICATION, BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 37
  • TABLE 8 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2027 (USD MILLION) 38
  • TABLE 9 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018-2027 (USD MILLION) 38
  • TABLE 10 GLOBAL HUMAN GENETICS MARKET FOR NEUROLOGY, BY COUNTRY, 2018-2027 (USD MILLION) 39
  • TABLE 11 GLOBAL HUMAN GENETICS MARKET FOR ASSISTED REPRODUCTION, BY COUNTRY, 2018-2027 (USD MILLION) 39
  • TABLE 12 GLOBAL HUMAN GENETICS MARKET FOR GYNECOLOGY, BY COUNTRY, 2018-2027 (USD MILLION) 40
  • TABLE 13 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018-2027 (USD MILLION) 40
  • TABLE 14 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 40
  • TABLE 15 GLOBAL HUMAN GENETICS MARKET FOR NEUROPEDIATRIC, BY COUNTRY, 2018-2027 (USD MILLION) 41
  • TABLE 16 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018-2027 (USD MILLION) 41
  • TABLE 17 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 43
  • TABLE 18 GLOBAL HUMAN GENETICS MARKET FOR NIPT, BY COUNTRY, 2018-2027 (USD MILLION) 44
  • TABLE 19 GLOBAL HUMAN GENETICS MARKET FOR CARRIER TESTING, BY COUNTRY, 2018-2027 (USD MILLION) 45
  • TABLE 20 GLOBAL HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2018-2027 (USD MILLION) 46
  • TABLE 21 GLOBAL HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY COUNTRY, 2018-2027 (USD MILLION) 47
  • TABLE 22 GLOBAL HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY COUNTRY, 2018-2027 (USD MILLION) 48
  • TABLE 23 GLOBAL HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY COUNTRY, 2018-2027 (USD MILLION) 48
  • TABLE 24 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY COUNTRY, 2018-2027 (USD MILLION) 49
  • TABLE 25 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 49
  • TABLE 26 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2027 (USD MILLION) 49
  • TABLE 27 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018-2027 (USD MILLION) 50
  • TABLE 28 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018-2027 (USD MILLION) 51
  • TABLE 29 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018-2027 (USD MILLION) 51
  • TABLE 30 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY, 2018-2027 (USD MILLION) 52
  • TABLE 31 US: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 53
  • TABLE 32 US: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 53
  • TABLE 33 US: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 54
  • TABLE 34 US: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 54
  • TABLE 35 US: HUMAN GENETICS MARKET FOR BY NGS, BY TYPE, 2018-2027 (USD MILLION) 54
  • TABLE 36 CANADA: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 55
  • TABLE 37 CANADA: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 55
  • TABLE 38 CANADA: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 56
  • TABLE 39 CANADA: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 56
  • TABLE 40 CANADA: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 56
  • TABLE 41 UK: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 57
  • TABLE 42 UK: HUMAN GENETICS MARKET FOR BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 57
  • TABLE 43 UK: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 58
  • TABLE 44 UK: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 58
  • TABLE 45 UK: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 58
  • TABLE 46 GERMANY: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 59
  • TABLE 47 GERMANY: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 59
  • TABLE 48 GERMANY: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 60
  • TABLE 49 GERMANY: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 60
  • TABLE 50 GERMANY: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 60
  • TABLE 51 SPAIN: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 61
  • TABLE 52 SPAIN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, FOR TYPE, 2018-2027 (USD MILLION) 61
  • TABLE 53 SPAIN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 62
  • TABLE 54 SPAIN: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 62
  • TABLE 55 SPAIN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 62
  • TABLE 56 JAPAN: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 63
  • TABLE 57 JAPAN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 63
  • TABLE 58 JAPAN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 64
  • TABLE 59 JAPAN: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 64
  • TABLE 60 JAPAN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 64
  • TABLE 61 OTHERS: HUMAN GENETICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 65
  • TABLE 62 OTHERS: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018-2027 (USD MILLION) 65
  • TABLE 63 OTHERS: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018-2027 (USD MILLION) 66
  • TABLE 64 OTHERS: HUMAN GENETICS MARKET, BY TEST, 2018-2027 (USD MILLION) 66
  • TABLE 65 OTHERS: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018-2027 (USD MILLION) 66
  • TABLE 66 MAJOR PLAYERS IN THE HUMAN GENETICS MARKET 67
  • TABLE 67 MOST ACTIVE PLAYER IN THE HUMAN GENETICS MARKET 70
  • TABLE 68 PRODUCT LAUNCH/PRODUCT APPROVAL 71
  • TABLE 69 MERGER & ACQUISITION 71
  • TABLE 70 EXPANSION 72
  • TABLE 71 MYRIAD GENETICS INC.: PRODUCT/SERVICE OFFERED 75
  • TABLE 72 MYRIAD GENETICS INC.: KEY DEVELOPMENTS 75
  • TABLE 73 SYNLAB GROUP: PRODUCT/SERVICE OFFERED 78
  • TABLE 74 SYNLAB GROUP: KEY DEVELOPMENTS 78
  • TABLE 75 EUROFINS MEGALAB S.A: PRODUCT/SERVICE OFFERED 81
  • TABLE 76 BIOMARKER TECHNOLOGIES: PRODUCT/SERVICE OFFERED 83
  • TABLE 77 ECHEVARNE LABORATORY: PRODUCT /SERVICE OFFERED 85
  • TABLE 78 ELABSCIENCE BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERED 87
  • TABLE 79 NIMGENETICS: PRODUCT/SERVICE OFFERED 89
  • TABLE 80 SISTEMAS GENOMICOS: PRODUCTS OFFERED 91
  • TABLE 81 FULLGENOMICS: PRODUCTS/SERVICES OFFERED 93
  • TABLE 82 GENINCODE: PRODUCTS/SERVICES OFFERED 95
  • TABLE 83 GENINCODE: KEY DEVELOPMENTS 95
  • TABLE 84 ATRYS HEALTH: PRODUCTS/SERVICES OFFERED 97
  • TABLE 85 GENYCA: PRODUCTS/SERVICES OFFERED 99
  • TABLE 86 IGENOMIX: PRODUCTS/SERVICES OFFERED 101
  • TABLE 87 IGENOMIX: KEY DEVELOPMENTS 101
  • TABLE 88 GENOLOGICA: PRODUCTS/SERVICES OFFERED 103
  • TABLE 89 BODE CELLMARK FORENSICS, INC.: PRODUCTS/SERVICES OFFERED 105

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS 14
  • FIGURE 2 GLOBAL HUMAN GENETICS MARKET 15
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22
  • FIGURE 4 MARKET DYNAMICS: GLOBAL HUMAN GENETICS MARKET 25
  • FIGURE 5 DRIVER IMPACT ANALYSIS 27
  • FIGURE 6 RESTRAINT IMPACT ANALYSIS 28
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL HUMAN GENETICS MARKET 29
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL HUMAN GENETICS MARKET 31
  • FIGURE 9 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 34
  • FIGURE 10 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2020 AND 2027 (USD MILLION) 42
  • FIGURE 11 GLOBAL HUMAN GENETICS MARKET SHARE (%), BY COUNTRY, 2020 52
  • FIGURE 12 BENCHMARKING OF MAJOR COMPETITORS 68
  • FIGURE 13 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE HUMAN GENETICS MARKET 69
  • FIGURE 14 HUMAN GENETICS MARKET: COMPETITIVE LANDSCAPE 71
  • FIGURE 15 SALES (USD MILLION), 2020 72
  • FIGURE 16 MYRIAD GENETICS INC.: FINANCIAL OVERVIEW SNAPSHOT 74
  • FIGURE 17 MYRIAD GENETICS INC.: SWOT ANALYSIS 76
  • FIGURE 18 SYNLAB GROUP: FINANCIAL OVERVIEW SNAPSHOT 77
  • FIGURE 19 SYNLAB GROUP: SWOT ANALYSIS 79
  • FIGURE 20 EUROFINS MEGALAB S.A.: FINANCIAL OVERVIEW SNAPSHOT 80
  • FIGURE 21 EUROFINS MEGALAB S.A: SWOT ANALYSIS 81
  • FIGURE 22 BIOMARKER TECHNOLOGIES: SWOT ANALYSIS 84
  • FIGURE 23 ECHEVARNE LABORATORY: SWOT ANALYSIS 86
  • FIGURE 24 ELABSCIENCE BIOTECHNOLOGY INC.: SWOT ANALYSIS 88
  • FIGURE 25 NIMGENETICS: SWOT ANALYSIS 90
  • FIGURE 26 SISTEMAS GENOMICOS: SWOT ANALYSIS 92
  • FIGURE 27 FULLGENOMICS: SWOT ANALYSIS 94
  • FIGURE 28 GENINCODE: SWOT ANALYSIS 96
  • FIGURE 29 ATRYS HEALTH: SWOT ANALYSIS 98
  • FIGURE 30 GENYCA: SWOT ANALYSIS 100
  • FIGURE 31 IGENOMIX: SWOT ANALYSIS 102
  • FIGURE 32 GENOLOGICA: SWOT ANALYSIS 104
  • FIGURE 33 BODE CELLMARK FORENSICS, INC.: SWOT ANALYSIS 106